EnzE - Enzyme based antibody Enhancement
Enzyme based antibody Enhancement – A short background description
Many antibody based cancer therapies relies on activation of the immune system via so called Antibody Dependent Cell-mediated Cytotoxicity (ADCC). The antibodies bind to antigens on cancer cells and once attached, the antibody attracts immune cells to destroy the cancer cells.
For instance, the anti-CD20 antibody which is used for treatment of lymphoma and leukemia, binds to surface molecules on cancer cells and activates cytotoxic immune cells to kill the cancer cells. The immune cells are activated through binding of the Fc-part of the antibody to so called Fc-gamma receptors on the cell surface of the immune cells.
The Fc-gamma receptors are involved in the therapeutic effector functions of many different antibodies and often needed to acquire sufficient effect. However, due to the abundancy of normal IgG in blood, the Fc-gamma receptors are occupied by IgG and the therapeutic antibodies has to compete for binding to the Fc-gamma receptors.
Hence pre-treatment with imlifidase or EndoS has the potential to potentiate presently available antibody based cancer therapies. Results from in vitro testing of the concept has been published in Journal of Molecular Biology, 2012 Jun 29;420(1-2):1-7.